Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers DOI Creative Commons
Hyeyoung Lee,

Geon Young Ko,

Ji‐Hyun Lee

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1350 - 1350

Published: Nov. 29, 2024

Background: Cellular and humoral immunity are key to the immune response against SARS-CoV-2, but comparability correlation across different assays remain underexplored. This study compares three T-cell antibody in two vaccine groups. Methods: prospective longitudinal cohort involved 46 naïve healthcare workers: a total of 11 homologous mRNA-1273 group (three doses) 35 heterologous ChAd (two doses followed by BNT booster). Blood samples were collected at five time points. was assessed using ELISPOT commercial interferon-gamma release assays: (IGRA)-QuantiFERON SARS-CoV-2 (QF) Covi-FERON ELISA (CoVF). Humoral evaluated IgG surrogate virus neutralization test. Results: The exhibited stronger more consistent responses than group. correlations between IGRA varied from weak moderate (ρ = 0.300–0.410), while QF-IGRA CoVF-IGRA showed 0.700–0.737). assay substantial agreement with QF [Ag2]-IGRA (k 0.697–0.774) CoVF [O-sp]-IGRA 0.641–0.718), an 80.4% rate 0.608) found [Ag2]- tests. Three demonstrated very strong each other near-perfect 0.866–0.949), 0.807–0.831), 0.753–0.777). Conclusions: SARS-CoV-2-specific cellular vary platform type, highlighting importance measuring both B-cell multiple comprehensively assess status.

Language: Английский

Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers DOI Creative Commons
Hyeyoung Lee,

Geon Young Ko,

Ji‐Hyun Lee

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1350 - 1350

Published: Nov. 29, 2024

Background: Cellular and humoral immunity are key to the immune response against SARS-CoV-2, but comparability correlation across different assays remain underexplored. This study compares three T-cell antibody in two vaccine groups. Methods: prospective longitudinal cohort involved 46 naïve healthcare workers: a total of 11 homologous mRNA-1273 group (three doses) 35 heterologous ChAd (two doses followed by BNT booster). Blood samples were collected at five time points. was assessed using ELISPOT commercial interferon-gamma release assays: (IGRA)-QuantiFERON SARS-CoV-2 (QF) Covi-FERON ELISA (CoVF). Humoral evaluated IgG surrogate virus neutralization test. Results: The exhibited stronger more consistent responses than group. correlations between IGRA varied from weak moderate (ρ = 0.300–0.410), while QF-IGRA CoVF-IGRA showed 0.700–0.737). assay substantial agreement with QF [Ag2]-IGRA (k 0.697–0.774) CoVF [O-sp]-IGRA 0.641–0.718), an 80.4% rate 0.608) found [Ag2]- tests. Three demonstrated very strong each other near-perfect 0.866–0.949), 0.807–0.831), 0.753–0.777). Conclusions: SARS-CoV-2-specific cellular vary platform type, highlighting importance measuring both B-cell multiple comprehensively assess status.

Language: Английский

Citations

0